Life sciences service providers leverage PAREXEL's eClinical solutions to simplify drug development for customers through technology partnership initiative
PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that clinical technology companies CRF Health and Clinical Ink have joined its Perceptive Partner Program. Through the program, technology, consulting, reseller and training companies, as well as contract research organizations (CROs), can enhance and broaden their services to biopharmaceutical customers by leveraging the Perceptive MyTrials eClinical platform along with clinical and technical support services.
Perceptive MyTrials is one of the industry’s leading suites of applications for managing clinical trials. Its flexible, open architecture allows partners to integrate targeted, specialized solutions within the platform. This gives their sponsor customers efficient access to clinical data and applications from a single source, allowing them to more efficiently and effectively manage critical trial activities.
“To better ensure the safety and timeliness of their trials, our customers are increasingly seeking efficient approaches to patient screening, enrollment and randomization,” said Rachael Wyllie, CEO of CRF Health. “As a Perceptive partner, we can address these needs by integrating our electronic Clinical Outcome Assessments [eCOA] offering with Perceptive MyTrials randomization and electronic data capture technologies.”
Ed Seguine, CEO of Clinical Ink, said, “Integrating solutions from Perceptive MyTrials into our SureSource clinical platform will provide sponsors with proven trial management solutions in a user-friendly tablet PC system. This presents a powerful combination of functionality and mobility.”
As study designs become increasingly complex, sponsors are relying on eClinical technologies to manage protocols and evolving regulatory requirements. Developed in 2013 and consisting of an ecosystem of technology and CRO partners, the Perceptive Partner Program offers support services and training that enable service providers to integrate their offerings with individual or collective Perceptive MyTrials applications including:
* DataLabs Electronic Data Capture (EDC)
* ClinPhone Randomization and Trial Supply Management (RTSM)
* IMPACT Clinical Trial Management System (CTMS)
* Electronic Patient Reported Outcomes (ePRO)
* Medical Imaging
* Perceptive MyTrials Data-Driven Monitoring
* LIQUENT Insight Regulatory Information Management
“Sponsors continue to seek fully integrated, best-of-breed technology solutions and clinical outsourcing services that can be efficiently managed,” said Graham Bunn, Vice President, Perceptive Partner Program. “Adding CRF Health and Clinical Ink to our partner program further reinforces its value proposition as the industry’s premier partnership initiative for simplifying drug development.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.